EP 3573955 A1 20191204 - COMPOUNDS FOR INHIBITING LRRK2 KINASE ACTIVITY
Title (en)
COMPOUNDS FOR INHIBITING LRRK2 KINASE ACTIVITY
Title (de)
VERBINDUNGEN ZUR HEMMUNG DER LRRK2-KINASE-AKTIVITÄT
Title (fr)
COMPOSÉS POUR INHIBER L'ACTIVITÉ KINASE LRRK2
Publication
Application
Priority
- CN 2017072589 W 20170125
- CN 2017072614 W 20170125
- CN 2018073833 W 20180123
Abstract (en)
[origin: WO2018137618A1] Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical compositions comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.
IPC 8 full level
A61K 31/416 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); C07D 231/56 (2006.01)
CPC (source: EP US)
A61P 25/14 (2017.12 - EP); A61P 25/16 (2017.12 - EP US); A61P 25/28 (2017.12 - EP); C07D 407/14 (2013.01 - US); C07D 413/14 (2013.01 - EP US); C07D 471/10 (2013.01 - EP); C07D 487/04 (2013.01 - EP US); C07D 487/10 (2013.01 - EP US); C07D 491/048 (2013.01 - EP US); C07D 491/052 (2013.01 - EP); C07D 498/04 (2013.01 - US); C07D 498/10 (2013.01 - EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2018137618 A1 20180802; BR 112019015314 A2 20200519; CA 3049820 A1 20180802; CN 110234629 A 20190913; EP 3573955 A1 20191204; EP 3573955 A4 20200805; JP 2020505397 A 20200220; US 11034696 B2 20210615; US 2019359618 A1 20191128
DOCDB simple family (application)
CN 2018073833 W 20180123; BR 112019015314 A 20180123; CA 3049820 A 20180123; CN 201880008471 A 20180123; EP 18744181 A 20180123; JP 2019540060 A 20180123; US 201816480762 A 20180123